Monoclonal antibodies bevacizumab

S. K. Kelley, and A. Sandler. 2005. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-l/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer./. Clin. Oncol. 23 2544-2555. 

Multiple Adverse Events with a Monoclonal Antibody, Bevacizumab. 462... 

Bevacizumab (Avastin) Monoclonal antibody against ligand VEGFR Cancer Clinic... 

Bevacizumab is a humanized monoclonal antibody that binds to vascular endothelial growth factor, which prevents it from binding to its receptors, ultimately resulting in angiogenesis. 

Bevacizumab Monoclonal antibody that binds to Dose-limiting... 

The role of bevacizumab, a monoclonal antibody targeted against vascular endothelial growth factor, in MBC is currently not clearly defined. 

Bevacizumab is a humanized monoclonal antibody directed against vascular endothelial growth factor. Bevacizumab is associated with hypertension, which is easily managed with oral antihypertensive agents. 

Bevacizumab, a recombinant, humanized monoclonal antibody, neutralizes vascular endothelial growth factor. The addition of bevacizumab to doublet chemotherapy is recommended in advanced NSCLC of nonsqua-mous cell histology in patients with no history of hemoptysis and no CNS metastasis who are not receiving therapeutic anticoagulation. 

The three monoclonal antibodies approved, noted in Table 23.1, in the last 7 years for treatment of patients with cancer include Alemtuzumab (Campath M) (Genzyme Corporation, Cambridge, MA, U.S.A.), Cetuzimab (Erbitux ) (ImClone Corporation, Branchburg, NJ, U.S.A.), and bevacizumab (Avastin ) (Genentech, South San Francisco, CA, U.S.A.). 

Finally, bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody has also been approved for treatment of colorectal and breast cancer. There are several... 

Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor. It should be used with caution in patients with a history of hypertension because of an increased risk of proteinuria and in patients with uncontrolled hypertension. Side-effects that may be expected include... 

Both normal cells and tumor cells require blood circulation to provide the oxygen and the nourishment they need to survive. Bevacizumab (Avastin ) is used to treat advanced forms of cancer of the digestive system it is a reengineered mouse monoclonal antibody that binds to a growth factor receptor required for the development of blood circulation around a tumor. 

Immunomodulators affect the functioning of the immune system. Immune functions may be promoted as well as suppressed by these agents. In this section interferon alpha, BCG, immunocyanin and aldesleukine and the monoclonal antibodies, alem-tuzumab, bevacizumab, cetuximab, trastuzumab, rit-uximab and ibritumomab tiuxetan will be briefly discussed. 

---